All In Biotech

Drug Trial Radar · NCT03682380

A Study of Seltorexant (JNJ-42847922) After Single-Dose Administration in Healthy Participants

An Open-Label, Randomized, Multi-panel, Crossover Study to Evaluate the Relative Oral Bioavailability and Food Effect of Seltorexant (JNJ-42847922) After Single-Dose Administration in Healthy Subjects

Last checked: Nov 20, 2026Latest source record: Apr 27, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 151 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

151

Actual

Start

Oct 1, 2018

Primary completion

Aug 23, 2019

Study completion Aug 23, 2019

Sponsor

Lead sponsor
Janssen Research & Development, LLCJohnson & Johnson (Janssen) (JNJ)
Sponsor type
Industry
First posted
Sep 24, 2018

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Crossover
Masking
None
Primary purpose
Other
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 55 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The purpose of this study is to compare the rate and extent of absorption (relative bioavailability) of seltorexant Phase 3 test formulation(s) relative to a reference Phase 2b tablet formulation dosed in the evening under fasted and semi-fasted conditions (3 hours after meal); to assess the effect of type and timing of the meal on the rate and extent of absorption of seltorexant Phase 3 tablet formulation (low dose and high dose strength) in healthy male and female participants; and to assess the pharmacokinetic of single-dose administration of low dose and high dose of seltorexant in healthy male and female participants 3 hours after meal.

Conditions

  • Healthy

Interventions

  • Seltorexant High DoseDrug

    In Part 1, Part 2, and Part 3 (3A and 3C), Seltorexant high dose (either a high dose tablet or two low dose tablets) will be administered orally.

  • Seltorexant Low DoseDrug

    In Part 3 (3B and 3C), Seltorexant low dose will be administered orally.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Maximum Observed Plasma Concentration (Cmax)Time frame: Predose up to 48 hours postdose
  2. Area Under the Plasma Concentration-Time Curve from the Time of Dosing to the Last Measurable Plasma Concentration (AUC[0-last])Time frame: Predose up to 48 hours postdose
  3. Area Under the Plasma Concentration-Time Curve Extrapolated to Infinite Time (AUC[0-infinity])Time frame: Predose, up to 48 hours postdose

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • PRAHS

    Salt Lake City, Utah

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.